Pharmafile Logo

News and Press Releases

Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer

Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...

Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025

GSK
980 Great West Rd, London TW8 9GS

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...

Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025

Pfizer
235 East 42nd Street NY, NY 10017

NICE recommends Yselty▼ (linzagolix) for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis

1 May 2025 -- London, UK -- Theramex is pleased to announce that the National Institute for Health and Care Excellence (NICE) has recommended NHS reimbursement of the extended indication...

Category: Other, Pharmaceutical
Posted: May 1, 2025

Theramex
customerservice.uk-ie@theramex.com
5th Floor, 50 Broadway, London, SW1H 0BL, UK

Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over

2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England...

Category: Clinical Trials, Other, Pharmaceutical
Posted: April 2, 2025

Sobi
info@sobi.com
Norra Stationsgatan 93A Stockholm

Over a thousand people with multiple myeloma may be eligible for treatment with Nexpovio▼ (selinexor) following NICE recommendation addressing ‘significant unmet need’ for this incurable blood cancer

NEXPOVIO has been recommended for use in the NHS, offering the opportunity to improve patient outcomes in this challenging and complex cancer NEXPOVIO has the potential to address significant treatment...

Category: Biotechnology, Pharmaceutical
Posted: April 22, 2024

Menarini
Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH

Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children

Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...

Category: Pharmaceutical
Posted: April 9, 2024

Gilead Sciences, Inc

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...

Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024

GSK
980 Great West Rd, London TW8 9GS

NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia

Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...

Category: Clinical Trials
Posted: February 15, 2024

GSK
980 Great West Rd, London TW8 9GS

NICE Recommends Lilly’s Mirikizumab (OMVOH) for the Treatment of Eligible Adults with Moderately to Severely Active Ulcerative Colitis.

22 September 2023 -- Basingstoke, UK -- Eli Lilly and Company announced today that the National Institute for Health and Care Excellence (NICE) have recommended mirikizumab for the treatment of...

Category: Pharmaceutical
Posted: September 22, 2023

Eli Lilly
ukpublicaffairs@lilly.com
450 Kendall Street Cambridge, MA 02142